RRA
AKBA icon

Round Rock Advisors’s Akebia Therapeutics AKBA Stock Holding History

Round Rock Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$231K Hold
166,089
– – 0.04% 297
2025
Q4 		$267K Buy
166,089
+22,841
+16% +$47.8K 0.04% 288
2025
Q3 		$427K Buy
+143,248
New +$477K 0.07% 195

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Round Rock Advisors's AKBA Position: Q1 2026 in Review

Round Rock Advisors held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 166,089 shares worth $231K. The position accounts for 0.04% of the portfolio, ranked #297.

Round Rock Advisors first reported a position in AKBA in Q3 2025 and has held it in 3 quarters since. The position peaked at $427K in Q3 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • Round Rock Advisors held 166,089 shares of Akebia Therapeutics worth $231K as of Q1 2026.
  • Round Rock Advisors left its Akebia Therapeutics share count unchanged in Q1 2026.
  • Akebia Therapeutics made up 0.04% of Round Rock Advisors's portfolio in Q1 2026, its #297 holding.
  • Round Rock Advisors first reported a position in Akebia Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Round Rock Advisors's Akebia Therapeutics position peaked at $427K in Q3 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on Round Rock Advisors's 13F filing for Q1 2026, filed 15 May 2026.